NEW Our free Dividend Tracker is live — see what your stocks pay you
Add your stocks and see every dividend they pay you — dates, amounts, and reinvested shares.
Start Free »

BYSI | NASDAQ

$0.77 -$0.35 | -31.25%
SIGNAL:Signal available — unlock to view |2026-09-28 |F&G 5 |RSI 76.0

Company Overview:

Market Cap: $31.80M
Trailing PE: N/A
FWD PE: —
Payout Ratio (TTM): —
52-Week Range: $0.57 - $2.44

9.6 Year BYSI Performance Metrics:

Total Return (with DRIP): -95.4% (-27.47% CAGR)
Total Return (no DRIP): -95.4% (-27.47% CAGR)
Share Price: -95.4% (-27.47% CAGR)
Yield on Cost (with DRIP): —
Total Invested: $10,000
Total Value (with DRIP): $458
Total Return $ (with DRIP): -$9,542
BYSI Total Return
1M 3M 6M YTD 1Y 3Y 5Y 10Y
BYSI Price Chart
1M 3M 6M YTD 1Y 3Y 5Y 10Y All

Unlock All Reports & Research Dividend Stocks like a BOSS!

Save 25% with annual plan (3 Months Free)
Pro
$171 ($14.25/mo) $102.60/yr ($8.55/mo)
7-day free trial
  • Unlimited Portfolio Tracker
  • Portfolio - Lots/Sales/Dividends
  • Portfolio Auto-DRIP
  • Stock Fundamentals
  • DCF valuation modeling
  • Compare Stocks Side-by-Side
  • Revenue & EPS Estimates
Try it free for 7 days
You save $125.40 (55%)
Most Popular
Premium
$288 ($24/mo) $172.80/yr ($14.40/mo)
7-day free trial
  • Everything in Pro
  • YieldMax PNL Tracker
  • YieldMax NAV Erosion Alerts
  • Stocks Dashboard
Try it free for 7 days
You save $211.20 (55%)
Ultra
$576 ($48/mo) $345.60/yr ($28.80/mo)
7-day free trial
  • Everything in Premium
  • Group & weekly ETF estimates
  • YouTuber Mode
  • Trades summary + CSV export
  • Priority data & support
Try it free for 7 days
You save $422.40 (55%)

BYSI Fundamentals: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:

BYSI - Revenue
BYSI Revenue CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
BYSI - Earnings Per Share (EPS)
BYSI EPS CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
BYSI - Net Income
BYSI Net Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
BYSI - EBITDA
BYSI EBITDA CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
BYSI - Free Cash Flow
BYSI Free Cash Flow CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
BYSI - Free Cash Flow / Share
BYSI Free Cash Flow / Share CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
BYSI - Operating Income
BYSI Operating Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
BYSI - Gross Profit
BYSI Gross Profit CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
BYSI - Shares Outstanding
BYSI Shares Outstanding CAGR:1Y: 1.99%2Y: 2.59%5Y: 1.06%10Y: 10.02%
BYSI - Share Buybacks
BYSI Share Buybacks CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
BYSI - Stock-Based Comp
BYSI Stock-Based Comp CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
BYSI - Expenses
BYSI Expenses CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:

BYSI - REVENUE: Actual + Estimates
BYSI Actual Revenue CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
BYSI - EPS: Actual + Estimates
BYSI Actual EPS CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
BYSI - NET INCOME: Actual + Estimates
BYSI Actual Net Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
BYSI - EBITDA: Actual + Estimates
BYSI Actual EBITDA CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Ratios, Profit Margins & Return on Capital:

BYSI - Net Profit Margin
BYSI Net Profit Margin CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
BYSI - Gross Profit Margin
BYSI Gross Profit Margin CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
BYSI - Price to Earnings
BYSI Price to Earnings CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
BYSI - Price To Sales Ratio
BYSI Price To Sales Ratio CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
BYSI - Return on Capital Employed
BYSI Return on Capital Employed CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
BYSI - Return on Invested Capital
BYSI Return on Invested Capital CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Compare stocks side-by-side

Projected Future Returns & Dividends for BYSI

Based on past 9.6-year performance, here are BYSI growth metrics:

Share price CAGR of -27.47%
Dividend CAGR of +0%

Using BYSI CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

BYSI (DRIP)BYSI - No DRIP
Current Price$0.77$0.77
Start Shares12,987.0112,987.01
Start Value$10,000$10,000
  
After 10 years:
Final Share Count12,987.0112,987.01
Dividends Payment$0.00$0.00
Annual Dividends$0$0
Yield on cost0.00%0.00%
Share Price$0.03$0.77
Total Dividends$0$0
Final Value$403$10,000

Estimated Future Value + Dividends - BYSI

NOTE: Above numbers are our estimate based on BYSI's Dividend and Price CAGR over past 9.6 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Save 25% with annual plan (3 Months Free)
Pro
$171 ($14.25/mo) $102.60/yr ($8.55/mo)
7-day free trial
  • Unlimited Portfolio Tracker
  • Portfolio - Lots/Sales/Dividends
  • Portfolio Auto-DRIP
  • Stock Fundamentals
  • DCF valuation modeling
  • Compare Stocks Side-by-Side
  • Revenue & EPS Estimates
Try it free for 7 days
You save $125.40 (55%)
Most Popular
Premium
$288 ($24/mo) $172.80/yr ($14.40/mo)
7-day free trial
  • Everything in Pro
  • YieldMax PNL Tracker
  • YieldMax NAV Erosion Alerts
  • Stocks Dashboard
Try it free for 7 days
You save $211.20 (55%)
Ultra
$576 ($48/mo) $345.60/yr ($28.80/mo)
7-day free trial
  • Everything in Premium
  • Group & weekly ETF estimates
  • YouTuber Mode
  • Trades summary + CSV export
  • Priority data & support
Try it free for 7 days
You save $422.40 (55%)

Company Info

BeyondSpring Inc. (BYSI) had its IPO on 2017-03-09, and is traded on NASDAQ stock exchange.

BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced through Phase III clinical trials for two distinct applications: the prevention of chemotherapy-induced neutropenia, and the treatment of advanced non-small cell lung cancer. The company is also exploring Plinabulin's efficacy in combination with various immuno-oncology drugs; specifically, alongside nivolumab (a PD-1 antibody) for NSCLC, and with nivolumab and ipilimumab (a CTLA-4 antibody) for small cell lung cancer (SCLC). Furthermore, it is being investigated in conjunction with PD-1 or PD-L1 antibodies and radiation to address a range of cancers. Beyond its lead asset, BeyondSpring's pipeline includes three preclinical-stage small molecule immune agents and a proprietary drug development platform. The company, founded in 2010, maintains its headquarters in New York, New York.

BYSI website: https://www.beyondspringpharma.com


Get Full Access to All Reports with DRIPCalc PRO

Save 25% with annual plan (3 Months Free)
Pro
$171 ($14.25/mo) $102.60/yr ($8.55/mo)
7-day free trial
  • Unlimited Portfolio Tracker
  • Portfolio - Lots/Sales/Dividends
  • Portfolio Auto-DRIP
  • Stock Fundamentals
  • DCF valuation modeling
  • Compare Stocks Side-by-Side
  • Revenue & EPS Estimates
Try it free for 7 days
You save $125.40 (55%)
Most Popular
Premium
$288 ($24/mo) $172.80/yr ($14.40/mo)
7-day free trial
  • Everything in Pro
  • YieldMax PNL Tracker
  • YieldMax NAV Erosion Alerts
  • Stocks Dashboard
Try it free for 7 days
You save $211.20 (55%)
Ultra
$576 ($48/mo) $345.60/yr ($28.80/mo)
7-day free trial
  • Everything in Premium
  • Group & weekly ETF estimates
  • YouTuber Mode
  • Trades summary + CSV export
  • Priority data & support
Try it free for 7 days
You save $422.40 (55%)
Loading signals…

DCF Model — BYSI

Value from:
Pay up to today
—
vs current price $0.77
—
Cash flow & implied price by year

FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.

EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.

Free cash flow today
—
grows for the next years
Then mature
—
every future dollar counted back to today
Pile of today-dollars
—
÷ shares
Implied price path
YearFCFImplied price
Sensitivity — fair value: growth ↓ × target return →